RedHill Biopharma (RDHL) Equity Ratio: 2013-2025
Historic Equity Ratio for RedHill Biopharma (RDHL) over the last 1 years, with Jun 2025 value amounting to -22.75.
- RedHill Biopharma's Equity Ratio fell 22.22% to -22.75 in Q2 2025 from the same period last year, while for Jun 2025 it was -22.75, marking a year-over-year decrease of 22.22%. This contributed to the annual value of -0.26 for FY2024, which is 389.11% down from last year.
- Per RedHill Biopharma's latest filing, its Equity Ratio stood at -22.75 for Q2 2025, which was down 8,667.12% from -0.26 recorded in Q4 2024.
- Over the past 5 years, RedHill Biopharma's Equity Ratio peaked at 0.09 during Q4 2023, and registered a low of -22.75 during Q2 2025.
- Moreover, its 3-year median value for Equity Ratio was -10.90 (2023), whereas its average is -10.49.
- As far as peak fluctuations go, RedHill Biopharma's Equity Ratio slumped by 721.96% in 2022, and later soared by 129.47% in 2023.
- RedHill Biopharma's Equity Ratio (Quarterly) stood at 0.05 in 2021, then tumbled by 721.96% to -0.30 in 2022, then skyrocketed by 129.47% to 0.09 in 2023, then plummeted by 389.11% to -0.26 in 2024, then dropped by 22.22% to -22.75 in 2025.
- Its Equity Ratio stands at -22.75 for Q2 2025, versus -0.26 for Q4 2024 and -18.62 for Q2 2024.